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different rare heterozygous variants in eight genes: two 
pathogenic, one likely pathogenic, twenty-one variants of 
unknown significance (VUS) and twenty-three unlikely 
pathogenic variants. In familial AAA we found one patho-
genic and segregating variant (COL3A1 p.Arg491X), one 
likely pathogenic and segregating (MYH11 p.Arg254Cys), 
and fifteen VUS. In sporadic patients we found one patho-
genic (TGFBR2 p.Ile525Phefs*18) and seven VUS. Thir-
teen patients had two or more variants. These results show 
a previously unknown association and overlapping genetic 
defects between AAA and familial thoracic aneurysms, 
indicating that genetic testing may help to identify the 
cause of familial and sporadic AAA. In this view, genetic 
testing of these genes specifically or in a genome-wide 
approach may help to identify the cause of familial and 
sporadic AAA.
Introduction
Approximately 20 % of the patients with an abdominal 
aortic aneurysm (AAA) have a positive family history for 
aneurysms, suggesting a genetic predisposition for AAA in 
these families (Rossaak et al. 2001; Salo et al. 1999; van 
de Luijtgaarden et al. 2014). The genetic aortic aneurysm 
syndromes Marfan, Loeys–Dietz, and aneurysms-osteo-
arthritis (AOS), involving the FBN1, TGFBR1, TGFBR2, 
TGFB2, and SMAD3 genes were first identified in patients 
with pathologic dilatation or aneurysm of the thoracic 
aorta with multisystem overlapping cardiovascular, skel-
etal and ocular manifestations (Boileau et al. 2012; Cook 
et al. 2014; Dietz et al. 1991; Loeys et al. 2006; van de 
Laar et al. 2011). The genetic defects in these syndromes 
affect the integrity of the elastic medial layer by inference 
with the transforming growth factor-beta (TGF-β) pathway 
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(Boileau et al. 2012; Judge and Dietz 2005; Lindsay et al. 
2012; Loeys et al. 2005; ten Dijke and Arthur 2007). 
The wide range of variably expressed features in these 
rare autosomal dominantly inherited syndromic forms of 
familial thoracic aneurysm includes pectus- and/or spinal 
deformities, joint laxity, and skin translucency and spe-
cifically for AOS, osteoarthritis and for the Loeys–Dietz 
syndrome, hypertelorism, bifid uvula or cleft palate and 
arterial tortuosity. Vascular tortuosity, ascending aortic 
aneurysm, joint laxity and pectus excavatum are also main 
features of the EFEMP2-related autosomal recessive juve-
nile cutis laxa syndrome (Hucthagowder et al. 2006; Kap-
panayil et al. 2012).
In another group of families with thoracic aneurysm 
without distinct clinical features, genetic defects were 
identified in the so-called non-syndromic familial thoracic 
aneurysm genes including the MYH11, MYLK and ACTA2 
that affect smooth muscle cell (SMC) functioning (Kuang 
et al. 2012; Pannu et al. 2007; Renard et al. 2013; Wang 
et al. 2010). These may also affect TGF-β signaling, like 
ACTA2 mutations, occurring in 16 % of patients with 
familial thoracic aortic aneurysm and in sporadic thoracic 
aortic aneurysms and dissections associated with medial 
degeneration, focal medial smooth muscle cell hyperplasia 
and proliferation, and stenotic arteries in the vaso-vaso-
rum (Guo et al. 2007; Morisaki et al. 2009; Renard et al. 
2013). A recent review estimates that approximately 20 % 
of familial thoracic aneurysm cases could be explained by 
a mutation in one of the thoracic aneurysm genes (Pomi-
anowski and Elefteriades 2013). Establishing the exact 
contribution of each of these genes in (familial) thoracic 
aneurysms has been hampered by the overlap in clinical 
features. Occasionally isolated abdominal aortic aneu-
rysms have been observed in families with familial syn-
dromic and non-syndromic thoracic aneurysm. Therefore, 
genes associated with the familial thoracic aortic aneurysm 
may play a role in the degenerative changes of the extra-
cellular matrix of the abdominal aortic wall underlying the 
formation of AAA. For this reason, we decided to screen 
AAA patients for variants in the transforming growth fac-
tor-beta pathway genes EFEMP2, FBN1, SMAD3, TGBF2, 
TGFBR1, TGFBR2, smooth muscle cells genes ACTA2, 
MYH11 and MYLK, as well as the vascular Ehlers–Dan-
los gene COL3A1, which is associated with vascular fra-
gility (Pepin et al. 2000). In addition, we investigated 
the previously reported association between abdominal 
aneurysm and the c.665C>T variant in MTHFR (Thomp-
son et al. 2008). We report all the variants found in these 
analyses, except those classified as clearly not pathogenic 
(benign). The presented description of variants will convey 
relevance for classification of variants in future diagnostic 
setting.
Materials and methods
The study complied with the declaration of Helsinki 
and was approved by the Institutional Review Board 
(MEC-2013-265).
Study population
The study population consisted of 155 AAA patients 
referred for genetic counseling between January 2009 and 
December 2013 to the Department of Clinical Genetics at 
the Erasmus University Medical Center in Rotterdam, the 
Netherlands. Abdominal aortic aneurysm was defined as 
an external infrarenal abdominal aortic diameter ≥30 mm 
(Moll et al. 2011). Patients were classified as familial AAA 
when at least one first-degree relative (i.e., parent, sibling 
or child) was confirmed by medical records to be diag-
nosed with an aortic aneurysm (n = 99, 81 male). Patients 
reporting only affected second- or third-degree relatives 
were also classified as sporadic AAA, because the report-
ing of medical information of second- or third-degree rela-
tives was considered less reliable (Andreasen et al. 1977). 
Patients without an affected first-degree relative were clas-
sified as sporadic AAA (n = 56, 46 male). In case of famil-
ial AAA, the first family member diagnosed with AAA was 
included as index in the study. Cases of concordant twins 
were considered as familial AAA. Genetic evaluation of 
the AAA patients was performed by a clinical geneticist 
and included ascertainment of a detailed family history 
and physical examination. All patients consented to DNA 
testing.
DNA analysis and classification of variants
Sanger sequencing of all coding exons and exon–intron bound-
aries in ACTA2 (NM_001613.1), COL3A1 (NM_000090.3), 
EFEMP2 (NM_016938.3), FBN1 (NM_000138.3), MYH11 
(NM_001040113.1), MYLK (NM_053025.3), SMAD3 
(NM_005902.3), TGFB2 (NM_001135599.2), TGFBR1 
(NM_004612.2) and TGFBR2 (NM_001024847.2) was per-
formed at the certified laboratories of the Departments of 
Clinical Genetics of the Erasmus University Medical Center 
in Rotterdam and the VU Medical Center in Amsterdam. 
Patients were tested for the p.Ala222Val variant in MTHFR 
(NM_005957.4) at the Department of Clinical Genetics at the 
University Hospital in Nijmegen, The Netherlands.
Assessment of the pathogenic effect of genetic variants 
was performed according to the guidelines currently used in 
the Rotterdam laboratory for DNA diagnostics with the use 
of Alamut Interactive Biosoftware (Rouen, France). This 
software incorporates SpliceSiteFinder-like, MaxEntScan, 
NNSPLICE, GeneSplicer, and Human Splicing Finder for 
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the prediction of splicing variants and the programs Align 
GVGD, SIFT, Mutation Taster, PolyPhen-2 and KDv4 for 
in silico prediction of the effect of amino acid changes. 
Additionally, it gives population frequencies for dbSNP and 
ESP, and shows whether or not a variant has been reported 
before in Human Gene Mutation Database (HGMD). The 
Rotterdam classification system of variants was adapted 
from the sequence variation classification proposed by 
Plon et al. (2008). The criteria for classification of variants 
included the allele frequency in the dbSNP/ESP (cutoff 
0.01), predicted effects on splicing, the in silico predic-
tion of effect on the protein and previously described links 
to disease. Exonic variants remote from wild-type splice 
donor and acceptor sites were assessed to have no effect 
on splicing. For each variant present in HGMD the sup-
porting evidence was reviewed and we evaluated whether 
previous reports linking specific variants to aneurysm were 
supported by functional studies or expression assays. Addi-
tionally, a variant only predicted by in silico prediction to 
be pathogenic would not automatically be classified as such 
because of lack of functional evidence. This resulted in cat-
egorizing variants into five classes: pathogenic, likely path-
ogenic, unknown significance (VUS), likely benign, and 
benign (Table 1; Richards et al. 2015). All variants expect 
those classified as benign were reported in this paper. A 
single previous description of a variant in a patient was not 
considered as sufficient evidence for causation and these 
variants were classified as variants of unknown significance 
instead of likely pathogenic. In addition, Table 2 presents 
the allele frequencies of the variants in the Dutch popula-
tion derived from the GoNL cohort which contains data 
from parent–child combinations (Genome of the Nether-
lands 2014). From this source, only the information from 
the parents (n = 499) was used to compare the minor allele 
frequency (MAF) in the Dutch population to the allele fre-
quencies derived from Alamut. We choose to add this infor-
mation because the study population was predominantly 
(≥95 %) of Dutch ancestry and population-specific allele 
frequencies may help categorization of variants. Familial 
segregation of the variants with aneurysms in families was 
examined when affected relatives were available and con-
sented for DNA testing.
Results
Forty-seven variants were detected in 31 familial AAA 
(31 %) patients and 12 sporadic AAA (21 %) patients in 
COL3A1, EFEMP2, FBN1, MYH11, MYLK, TGBF2, 
TGFBR1, and TGFBR2, no variants were found in ACTA2 
and SMAD3 (Table 2).
Pathogenic variants
Two variants were classified as pathogenic. A COL3A1 
null mutation p.Arg491X was observed, segregating in 
patients with aneurysms in one family. This null mutation 
was observed in a 49-year-old man diagnosed with a small 
dissection of the arteria lienalis at screening for familial 
abdominal aneurysms (Supplementary online table). His 
paternal aunt who had a successful repair of an infrare-
nal aneurysm at age 69 also had the mutation. Her brother 
was reported with a sudden death at age 32 years. No 
autopsy was performed. Screening for the COL3A1 muta-
tion detected one asymptomatic 50-year-old female carrier 
without signs of vascular pathology on computed tomogra-
phy angiography. None of the carriers of the null mutations 
showed distinct loss of subcutaneous fat, skin fragility, 
abnormal scarring or suffered from complications or bleed-
ing after surgery or childbirth.
A novel heterozygous single base pair deletion in 
TGFBR2, p.Ile525Phefs*18 was found de novo in a 
47-year-old male presenting with complex vascular pathol-
ogy. This patient presented at the emergency room with 
severe acute abdominal pain and was diagnosed with a Stan-
ford type-B aortic dissection associated with a pre-existing 
Table 1  Classification of 
variants
Class Variant
Benign Frequency in population ≥0.01
Likely benign Intronic or silent variants with no effect on splicing, missense variants for which 
4/5 or 3/4 in silico protein predictions are neutral
Unknown significance Intronic, silent or missense variants that affect splicing, in-frame deletions/inser-
tions, missense variants for which more than 2 in silico protein predictions are 
damaging
Likely pathogenic Frameshift, nonsense or intronic variants that affect splicing in a way that a new 
in-frame protein is created, missense variants that have previously been linked to 
disease in HGMD
Pathogenic Frameshift, nonsense or intronic variants that affect splicing in a way that no in-
frame protein can be created
884 Hum Genet (2015) 134:881–893
1 3
Ta
bl
e 
2 
 V
ar
ia
nt
s 
in
 f
am
ili
al
 a
nd
 s
po
ra
di
c 
ab
do
m
in
al
 a
or
tic
 a
ne
ur
ys
m
G
en
e/
va
ri
an
t
Pr
ot
ei
n 
ch
an
ge
db
SN
P 
ID
M
A
F/
M
A
C
Sp
lic
e 
si
te
  
pr
ed
ic
tio
n
Pr
ed
ic
te
d 
pa
th
o-
ge
ni
c 
ef
fe
ct
 o
n 
pr
ot
ei
n 
(i
n 
si
lic
o,
  
n 
pr
og
ra
m
s)
A
m
in
o 
ac
id
  
co
ns
er
va
tio
n 
(n
 
sp
ec
ie
s)
C
la
ss
ifi
ca
tio
n
N
um
be
r 
of
  
va
ri
an
ts
 (
fa
m
ili
al
/
sp
or
ad
ic
 A
A
A
) 
(9
9/
56
)
Se
gr
eg
at
io
na
M
A
F 
G
oN
L
b
C
O
L
3A
1
3 
(3
/0
)
 c
.8
12
G
>
A
 (
Pi
ck
up
 
an
d 
Po
lla
ne
n 
20
11
)c
p.
A
rg
27
1G
ln
rs
11
21
85
88
7
0.
00
1/
1
N
o 
ef
fe
ct
2/
5
M
od
er
at
el
y 
co
n-
se
rv
ed
 (
9)
V
U
S
1 
(1
/0
)
nd
0.
00
4
 c
.8
98
-1
4A
>
G
In
tr
on
ic
–
–
E
ff
ec
t
–
–
V
U
S
1 
(1
/0
)
nd
na
 c
.1
47
1C
>T
p.
A
rg
49
1X
–
–
N
o 
ef
fe
ct
–
–
P
1 
(1
/0
)
+
na
E
F
E
M
P
2
6 
(6
/0
)
 c
.1
60
+1
7G
>
T
In
tr
on
ic
–
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
nd
na
 c
.2
77
G
>
A
c
p.
G
ly
93
Se
r
rs
22
34
46
2
0.
00
1/
3
N
o 
ef
fe
ct
0/
4
M
od
er
at
el
y 
co
n-
se
rv
ed
 (
10
)
L
B
3 
(3
/0
)
−/
nd
0.
00
5
 c
.3
68
-4
G
>
A
In
tr
on
ic
rs
11
15
50
97
3
0.
00
2/
4
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
−
0.
00
7
 c
.1
04
7C
>
T
c
no
-c
ha
ng
e
–
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
nd
na
F
B
N
1
8 
(5
/3
)
 c
.5
9A
>
G
 
(A
rb
us
tin
i e
t a
l. 
20
05
)c
,d
p.
Ty
r2
0C
ys
rs
20
13
09
31
0
–
N
o 
ef
fe
ct
0/
4
M
od
er
at
el
y 
co
n-
se
rv
ed
 (
11
)
V
U
S
1 
(0
/1
)
na
 c
.2
48
-1
7C
>
G
c
In
tr
on
ic
–
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
−
na
 c
.1
10
8G
>
A
c
p.
V
al
37
0l
le
–
–
N
o 
ef
fe
ct
0/
5
m
od
er
at
el
y 
co
n-
se
rv
ed
 (
11
)
L
B
1 
(1
/0
)
nd
na
 c
.2
26
0T
>
C
c
p.
Ty
r7
54
H
is
–
–
N
o 
ef
fe
ct
4/
5
hi
gh
ly
 c
on
se
rv
ed
 
(1
1)
V
U
S
1 
(1
/0
)
nd
na
 c
.2
89
5G
 >
 A
#
no
-c
ha
ng
e
rs
14
05
91
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
nd
na
 c
.3
45
5C
>
T
 (
H
un
g 
et
 a
l. 
20
09
)d
p.
A
la
11
52
V
al
–
–
E
ff
ec
t
1/
5
H
ig
hl
y 
co
ns
er
ve
d 
(1
1)
V
U
S
1 
(0
/1
)
na
 c
.6
05
5G
>
A
 
(S
he
ik
hz
ad
eh
 
et
 a
l. 
20
12
)d
p.
G
lu
20
19
Ly
s
–
–
N
o 
ef
fe
ct
3/
5
H
ig
hl
y 
co
ns
er
ve
d 
(1
1)
V
U
S
1 
(1
/0
)
nd
0.
00
1
 c
.7
41
2C
>
G
p.
Pr
o2
47
1A
rg
rs
19
39
22
23
3
–
N
o 
ef
fe
ct
3/
5
H
ig
hl
y 
co
ns
er
ve
d 
(1
1)
V
U
S
1 
(0
/1
)
na
M
Y
H
11
11
 (
9/
2)
 c
.7
60
C
>T
 (
K
ua
ng
 
et
 a
l. 
20
12
)a
p.
A
rg
25
4C
ys
rs
15
07
59
46
1
0.
00
1/
2
N
o 
ef
fe
ct
3/
4
H
ig
hl
y 
co
ns
er
ve
d 
(1
3)
L
P
1 
(1
/0
)
+
0.
00
8
 c
.9
56
A
>
G
p.
A
sn
31
9S
er
rs
14
99
64
92
8
–
E
ff
ec
t
1/
4
H
ig
hl
y 
co
ns
er
ve
d 
(1
3)
V
U
S
1 
(1
/0
)
−
na
 c
.1
52
3G
>
A
p.
A
rg
50
8H
is
rs
14
42
44
23
9
0.
00
1/
2
N
o 
ef
fe
ct
3/
4
H
ig
hl
y 
co
ns
er
ve
d 
(1
3)
V
U
S
1 
(1
/0
)
nd
na
885Hum Genet (2015) 134:881–893 
1 3
Ta
bl
e 
2 
 c
on
tin
ue
d
G
en
e/
va
ri
an
t
Pr
ot
ei
n 
ch
an
ge
db
SN
P 
ID
M
A
F/
M
A
C
Sp
lic
e 
si
te
  
pr
ed
ic
tio
n
Pr
ed
ic
te
d 
pa
th
o-
ge
ni
c 
ef
fe
ct
 o
n 
pr
ot
ei
n 
(i
n 
si
lic
o,
  
n 
pr
og
ra
m
s)
A
m
in
o 
ac
id
  
co
ns
er
va
tio
n 
(n
 
sp
ec
ie
s)
C
la
ss
ifi
ca
tio
n
N
um
be
r 
of
  
va
ri
an
ts
 (
fa
m
ili
al
/
sp
or
ad
ic
 A
A
A
) 
(9
9/
56
)
Se
gr
eg
at
io
na
M
A
F 
G
oN
L
b
 c
.1
86
8C
>
G
p.
A
la
62
3G
ly
rs
14
06
88
58
7
–
N
o 
ef
fe
ct
1/
4
hi
gh
ly
 c
on
se
rv
ed
 
(1
3)
L
B
1 
(1
/0
)
−
na
 c
.2
88
1-
14
C
>
G
In
tr
on
ic
–
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
+
na
 c
.4
69
4C
>
T
c
p.
T
hr
15
65
M
et
rs
11
18
54
56
3
0.
00
1/
1
N
o 
ef
fe
ct
3/
4
M
od
er
at
el
y 
co
n-
se
rv
ed
 (
13
)
V
U
S
1 
(1
/0
)
ge
m
0.
00
4
 c
.5
58
7C
>
T
c
no
-c
ha
ng
e
rs
14
26
39
68
8
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
nd
0.
00
4
 c
.5
63
5-
7G
>
A
c
In
tr
on
ic
rs
20
21
20
79
2
0.
00
1/
1
N
o 
ef
fe
ct
–
–
L
B
2 
(1
/1
)
nd
na
 c
.5
69
7G
>
C
c
p.
G
lu
18
99
A
sp
rs
11
39
64
17
3
0.
00
5/
10
N
o 
ef
fe
ct
4/
4
H
ig
hl
y 
co
ns
er
ve
d 
(1
3)
V
U
S
1 
(1
/0
)
−
0.
00
8
 c
.5
80
8-
11
_-
8d
el
In
tr
on
ic
–
–
E
ff
ec
t
–
–
V
U
S
1 
(0
/1
)
na
M
Y
L
K
19
 (
13
/6
)
 c
.3
12
T
>
C
no
-c
ha
ng
e
rs
14
75
97
39
8
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
ge
m
na
 c
.7
45
T
>
G
p.
Se
r2
49
A
la
–
–
N
o 
ef
fe
ct
2/
5
H
ig
hl
y 
co
ns
er
ve
d 
(7
)
V
U
S
1 
(0
/1
)
na
 c
.1
31
4C
 >
 T
no
-c
ha
ng
e
rs
20
04
23
95
4
0.
00
1/
2
N
o 
ef
fe
ct
–
–
L
B
1 
(0
/1
)
0.
00
1
 c
.1
32
7C
>
T
c
p.
Pr
o4
43
Se
r
rs
35
15
63
60
0.
00
6/
13
N
o 
ef
fe
ct
4/
5
H
ig
hl
y 
co
ns
er
ve
d 
(7
)
V
U
S
4 
(4
/0
)
-/
nd
0.
01
4
 c
.2
10
1G
 >
 A
p.
A
la
70
1T
hr
rs
14
28
35
59
6
0.
00
3/
7
N
o 
ef
fe
ct
2/
5
H
ig
hl
y 
co
ns
er
ve
d 
(7
)
V
U
S
1 
(0
/1
)
na
 c
.3
18
4G
>
T
c
p.
A
la
10
62
Se
r
rs
11
55
85
50
–
N
o 
ef
fe
ct
0/
5
H
ig
hl
y 
co
ns
er
ve
d 
(7
)
L
B
1 
(0
/1
)
na
 c
.3
30
2A
>
G
#
p.
Ly
s1
10
1A
rg
–
–
N
o 
ef
fe
ct
0/
5
H
ig
hl
y 
co
ns
er
ve
d 
(7
)
L
B
1 
(1
/0
)
−
na
 c
.3
40
3G
>
A
p.
G
ly
11
35
A
rg
–
–
N
o 
ef
fe
ct
4/
5
H
ig
hl
y 
co
ns
er
ve
d 
(7
)
V
U
S
1 
(1
/0
)
+
na
 c
.3
58
3A
>
G
c
p.
A
sn
11
95
A
sp
–
–
N
o 
ef
fe
ct
3/
5
H
ig
hl
y 
co
ns
er
ve
d 
(7
)
V
U
S
1 
(1
/0
)
nd
na
 c
.4
17
9C
>
T
no
-c
ha
ng
e
–
–
N
o 
ef
fe
ct
–
–
L
B
2 
(1
/1
)
−
na
 c
.4
76
4G
>
A
c
no
-c
ha
ng
e
rs
56
05
68
23
0.
00
3/
6
N
o 
ef
fe
ct
–
–
L
B
3 
(2
/1
)
nd
0.
00
8
 c
.4
78
5C
>
T
no
-c
ha
ng
e
–
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
nd
na
 c
.5
07
9G
>
A
c
no
-c
ha
ng
e
rs
14
14
67
67
5
0.
00
2/
5
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
nd
na
T
G
F
B
2
2 
(2
/0
)
 c
.2
72
G
>
A
c
p.
A
rg
91
H
is
rs
10
48
27
21
0.
00
1/
3
N
o 
ef
fe
ct
3/
4
H
ig
hl
y 
co
ns
er
ve
d 
(1
2)
V
U
S
1 
(1
/0
)
nd
0.
00
5
 c
.7
03
G
>
C
p.
V
al
23
5L
eu
rs
10
48
28
10
0.
00
1/
2
N
o 
ef
fe
ct
2/
4
hi
gh
ly
 c
on
se
rv
ed
 
(1
2)
V
U
S
1 
(1
/0
)
nd
0.
00
6
886 Hum Genet (2015) 134:881–893
1 3
Ta
bl
e 
2 
 c
on
tin
ue
d
G
en
e/
va
ri
an
t
Pr
ot
ei
n 
ch
an
ge
db
SN
P 
ID
M
A
F/
M
A
C
Sp
lic
e 
si
te
  
pr
ed
ic
tio
n
Pr
ed
ic
te
d 
pa
th
o-
ge
ni
c 
ef
fe
ct
 o
n 
pr
ot
ei
n 
(i
n 
si
lic
o,
  
n 
pr
og
ra
m
s)
A
m
in
o 
ac
id
  
co
ns
er
va
tio
n 
(n
 
sp
ec
ie
s)
C
la
ss
ifi
ca
tio
n
N
um
be
r 
of
  
va
ri
an
ts
 (
fa
m
ili
al
/
sp
or
ad
ic
 A
A
A
) 
(9
9/
56
)
Se
gr
eg
at
io
na
M
A
F 
G
oN
L
b
T
G
F
B
R
1
5 
(4
/1
)
 c
.1
5C
>
T
c
no
-c
ha
ng
e
–
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
nd
na
 c
.2
14
A
>
T
p.
Il
e7
2L
eu
rs
11
15
13
62
7
–
N
o 
ef
fe
ct
2/
5
H
ig
hl
y 
co
ns
er
ve
d 
(1
2)
V
U
S
2 
(1
/1
)
−
na
 c
.9
27
G
>
C
c
no
-c
ha
ng
e
–
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
nd
na
 c
.1
12
5A
>
C
c
no
-c
ha
ng
e
rs
78
61
78
0
0.
00
3/
6
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
nd
0.
00
4
T
G
F
B
R
2
3 
(2
/1
)
 c
.1
13
7C
>
T
no
-c
ha
ng
e
rs
11
31
94
60
8
–
N
o 
ef
fe
ct
–
–
L
B
1 
(1
/0
)
+
0.
00
4
 c
.1
23
4G
>
A
 
(M
at
ya
s 
et
 a
l. 
20
06
)c
,d
p.
V
al
41
2M
et
rs
35
76
66
12
0.
00
1/
1
N
o 
ef
fe
ct
3/
4
H
ig
hl
y 
co
ns
er
ve
d 
(1
4)
V
U
S
1 
(1
/0
)
ge
m
0.
00
2
 c
.1
57
3d
el
A
c
p.
Il
e5
25
P
he
fs
*1
8
–
–
N
o 
ef
fe
ct
–
–
P
1 
(0
/1
)
na
In
 b
ol
d 
th
e 
va
ri
an
ts
 c
la
ss
ifi
ed
 p
at
ho
ge
ni
c 
or
 li
ke
ly
 p
at
ho
ge
ni
c
P
 p
at
ho
ge
ni
c,
 L
P
 li
ke
ly
 p
at
ho
ge
ni
c,
 V
U
S 
va
ri
an
t o
f 
un
kn
ow
n 
cl
in
ic
al
 s
ig
ni
fic
an
ce
, L
B
 li
ke
ly
 b
en
ig
n,
 M
A
F
 m
in
or
 a
lle
le
 f
re
qu
en
cy
, M
A
C
 m
in
or
 a
lle
le
 c
ou
nt
, n
a 
no
t a
pp
lic
ab
le
a  
 F
or
 f
am
ili
al
 A
A
A
, 
se
gr
eg
at
io
n 
of
 t
he
 v
ar
ia
nt
 i
n 
af
fe
ct
ed
 r
el
at
iv
es
 w
as
 i
nv
es
tig
at
ed
, 
(+
) 
va
ri
an
t 
pr
es
en
t 
in
 a
ll 
af
fe
ct
ed
 r
el
at
iv
es
 i
n 
on
e 
fa
m
ily
, 
(−
) 
va
ri
an
t 
di
d 
no
t 
se
gr
eg
at
e 
in
 a
 f
am
ily
 w
ith
 
A
A
A
, (
nd
) 
se
gr
eg
at
io
n 
of
 th
e 
va
ri
an
t i
n 
fa
m
ili
al
 A
A
A
 w
as
 n
ot
 d
et
er
m
in
ed
, (
ge
m
) 
af
fe
ct
ed
 g
em
el
li 
w
ith
 v
ar
ia
nt
b  
 F
re
qu
en
cy
 in
 G
oN
L
 b
as
ed
 o
n 
49
9 
st
ud
ie
d 
in
di
vi
du
al
s,
 9
98
 a
lle
le
s,
 (
na
) 
va
ri
an
t w
as
 n
ot
 r
ep
or
te
d 
in
 G
oN
L
 d
at
a
c  
 V
ar
ia
nt
 is
 in
vo
lv
ed
 in
 c
om
pl
ex
 g
en
ot
yp
es
d  
 V
ar
ia
nt
 r
ep
or
te
d 
in
 a
ne
ur
ys
m
 p
at
ie
nt
 in
 H
G
M
D
887Hum Genet (2015) 134:881–893 
1 3
large aorto-iliac aneurysm and marked aorta-iliacal aneu-
rysm with tortuosity with a diameter of 98.5 mm. The 
ascending aortic diameter was normal measuring 32.0 mm. 
The patient was treated with β-blockade and blood pressure 
control, resulting in complete remission of symptoms. Two 
weeks after onset of the symptoms, the aorto-iliac aneu-
rysm was successfully repaired with an aorto-bifemoral 
Dacron bypass (van de Luijtgaarden et al. 2013). Marked 
arterial elongation and tortuosity of the abdominal aorta 
and iliac arteries was present without characteristic facial or 
musculo-skeletal signs of the Loeys–Dietz or Marfan syn-
drome. DNA analysis of his parents showed that the muta-
tion occurred de novo and no other relatives were affected. 
This patient also had a likely benign MYH11 intronic vari-
ant c.5635-7G > A just before exon 40. The likely benign 
MYH11 variant occurred also in his two unaffected sisters 
and their 74-year-old unaffected father.
Likely pathogenic variants
The missense variant in MYH11 (p.Arg254Cys) was clas-
sified as likely pathogenic because a report showing patho-
genic effects was available (Kuang et al. 2012). This vari-
ant was initially detected in a 73-year-old woman with a 
symptomatic abdominal aneurysm. The mutation was also 
present in her 44-year-old son diagnosed by family screen-
ing with bilateral aneurysm of the iliac arteries and a small 
abdominal aneurysm.
Variants of unknown significance (VUS)
Twenty-one VUS included 19 missense and 2 intronic vari-
ants. In familial cases 15 VUS were observed; 14 missense 
and one intronic. In sporadic cases, 7 VUS were observed; 
6 missense and one intronic. Two VUS were present in 
multiple patients. The MYLK (p.Pro443Ser) variant was 
found in four patients with familial AAA, but this variant 
did not segregate in one family and segregation could not 
be tested in the other families. The TGFBR1 (p.Ile72Leu) 
variant was present in one sporadic and one familial 
case, and did not segregate. Three VUS variants in FBN1 
(p.Tyr20Cys, p.Ala1152Val, and p.Glu2019Lys) were pre-
viously reported in patients with Marfan syndrome, with-
out sufficient evidence to be classified as likely pathogenic 
(Arbustini et al. 2005; Hung et al. 2009; Sheikhzadeh et al. 
2012). The TGFBR2 (p.Val412Met) variant in two affected 
twin brothers was previously reported in thoracic aneu-
rysm (Matyas et al. 2006). The VUS missense variant in 
COL3A1 (p.Arg271Gln) was previously linked to Ehlers–
Danlos syndrome in the literature, however, after critical 
evaluation of the report, the evidence for this link was con-
sidered not sufficient to classify the variant as pathogenic 
(Pickup and Pollanen 2011).
Likely benign variants (LB)
Of the twenty-three likely benign variants five were 
intronic, 13 were synonymous and 5 were missense vari-
ants. Four LB variants were observed in more than one 
patient: the synonymous MYLK c.4764G>A was present 
in three patients (two familial, one sporadic), the synony-
mous MYLK c.4179C>T and the intronic variant MYH11 
c.5635-7G>A occurred in one familial and one sporadic 
patient, and the missense EFEMP2 p.Gly93ser was present 
in three patients with familial AAA without evidence of 
segregation.
MTHFR c.665C>T
The MTHFR c.665C>T (p.Ala222Val) variant, previously 
reported as C677T, was tested in 130 patients (89 familial 
and 41 sporadic AAA patients). Twelve patients (9 %) were 
homozygous for the variant allele: ten (11 %) familial and 
two (5 %) sporadic. Forty-five (38 %) patients were het-
erozygous for the variant allele: thirty one (35 %) famil-
ial and fourteen (34 %) sporadic patients. The MAF in our 
study population was 0.265 compared to 0.320 in the Dutch 
GoNL cohort (Table 3).
Complex genotypes
Thirteen AAA patients (11 familial, including one pair of 
concordant monozygotic twins, and 2 sporadic) had two 
or more variants (Table 4). One pathogenic TGFBR2 was 
involved in a complex genotype with a likely benign vari-
ant in MYH11. 
Frequency of variants in the Dutch population
For 16 of the variants found in this study, the allele fre-
quency in the Dutch population was available from GoNL. 
The MAF of the VUS variant in MYLK (p.Pro443Ser) was 
0.014 in the Dutch population, and was reported in dbSNP 
with an MAF of 0.006. This indicates that this variant 
would be reclassified as a benign variant, using the GoNL 
frequency information instead of the frequency reported by 
dbSNP/ESP used in Alamut.
Discussion
The genetic defects causing familial abdominal aortic 
aneurysm are poorly understood. This study showed that 
genes known to be associated with inherited thoracic aor-
tic aneurysm also have a role in abdominal aortic aneu-
rysm. Our study is based on a group of AAA patients 
referred for counseling. Therefore, the observed results 
888 Hum Genet (2015) 134:881–893
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do not represent prevalence of variants in the Dutch AAA 
population. Although familial cases were overrepresented 
in the current study, a referral bias for genotype can be 
excluded, since there was no prior information on genetic 
defects in familial or sporadic AAA. The validation of our 
family history data showed that no relatives were reported 
incorrectly as affected, indicating that risk in relatives 
was not overestimated. On the other hand, underreport-
ing of familial disease may have happened, in particular 
for a disease like AAA, where aneurysms in relatives may 
go unnoticed and relatives could have undiagnosed aneu-
rysms or may have died before age of onset. It is, there-
fore, important to bear in mind that familial AAA cannot 
be excluded when family history of aneurysm is unin-
formative or missing.
This study investigated the association between AAA 
and the thoracic aneurysm genes ACTA2, COL3A1, 
EFEMP2, FBN1, MYH11, MYLK, SMAD3, TGBF2, 
TGFBR1, TGFBR2, and MTHFR (p.Ala222Val). There 
have been several large GWAS studies that found AAA risk 
alleles in LRP1, (Bown et al. 2011) DAP21P, (Gretarsdottir 
et al. 2010) ANRIL, (Helgadottir et al. 2008) and SORT1 
(Jones et al. 2013). These genes have not been tested in this 
study, but it would be useful to do so in future studies.
In this study, three variants were observed classified 
as pathogenic or likely pathogenic amongst a total of 47 
unique rare variants in our AAA study population of 155 
patients. Lack of a comprehensive overview of genetic vari-
ants in thoracic aneurysms precluded comparison of our 
findings in the abdominal aneurysm population to thoracic 
aneurysms population.
Assessment of pathogenicity of genetic variants remains 
a major challenge (MacArthur et al. 2014). Comprehensive 
guidelines are needed to distinguish true pathogenic from 
ambiguous variants with unknown clinical significance 
which constitutes a large part of the results of molecu-
lar analyses (Richards et al. 2015). Variants are listed in 
HGMD which reports whether variants and/or genes have 
been described in the literature as associated with dis-
ease requiring critical review of evidence presented to jus-
tify classification as likely pathogenic. Additional searches 
may be needed because not all known variants are listed in 
HGMD. Establishing a causal effect of variants involves 
finding a method of choice for functional testing of variants 
in aneurysm genes, which is complicated giving the like-
lihood of tissue-specific gene expression. Especially since 
nowadays abdominal aortic aneurysms are mostly restored 
by an endovascular procedure, no aortic aneurysm tissue 
from patients can be collected for functional testing.
Alamut incorporates allele frequency reported by 
dbSNP/ESP. The use of population-specific control cohorts, 
as GoNL in the current study, may improve correct clas-
sification of variants and prevent associating population-
specific polymorphisms with disease.
Significant co-segregation of a variant with disease 
provides evidence to support pathogenicity. In our study 
population it was often not possible to detect co-segre-
gation because AAA is a late onset disorder, where the 
Table 3  Frequencies of the MTHFR c.665C>T variant in AAA and control populations
a MAF in Dutch population: 0.320
References Patients (N) Diagnosis MAF Normal (CC) Heterozygote (CT) Homozygote (TT) CT and TT
Brunelli et al. (2000) 58 AAA 0.483 14 (24 %) 32 (55 %) 12 (21 %) 44 (76 %)
60 Control 0.392 19 (32 %) 35 (58 %) 6 (10 %) 41 (68 %)
Strauss et al. (2003) 63 AAA 0.365 21 (33 %) 38 (60 %) 4 (6 %) 42 (67 %)
75 Control 0.231 49 (65 %) 20 (27 %) 6 (8 %) 26 (35 %)
Jones et al. (2005, 2013) 428 AAAa 0.310 211 (49 %) 169 (40 %) 48 (11 %) 217 (51 %)
282 Control (healthy) 0.309 134 (48 %) 122 (43 %) 26 (9 %) 148 (52 %)
271 Control (CVD) 0.303 137 (51 %) 104 (38 %) 30 (11 %) 134 (49 %)
226 Control (PAD) 0.332 106 (47 %) 90 (40 %) 30 (13 %) 120 (53 %)
Sofi et al. (2005) 438 AAA 0.430 141 (32 %) 217 (50 %) 80 (18 %) 297 (68 %)
438 Controls 0.380 166 (38 %) 211 (48 %) 61 (14 %) 272 (62 %)
Ferrara et al. (2006) 42 AAA > 60 years 0.298 18 (43 %) 23 (55 %) 1 (2 %) 24 (57 %)
46 AAA < 60 years 0.424 10 (22 %) 33 (72 %) 3 (6 %) 36 (78 %)
45 Control 0.133 34 (75 %) 10 (23 %) 1 (2 %) 11(24 %)
Current study 130 AAA total 0.265a 73 (56 %) 45 (35 %) 12 (9 %) 57 (44 %)
89 AAA familial 0.287 48 (54 %) 31 (35 %) 10 (11 %) 41 (46 %)
41 AAA sporadic 0.220 25 (61 %) 14 (34 %) 2 (5 %) 16 (39 %)
Overall 1205 AAA 0.364 488 (40 %) 557 (46 %) 160 (13 %) 717 (60 %)
1397 Control 0.326 645 (46 %) 592 (42 %) 160 (11 %) 752 (54 %)
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majority of patients, familial AAA and sporadic AAA 
alike, are older than 65 years and most affected relatives 
are no longer alive. Although our results suggest that 
more variants occur in familial cases (31 %) than in spo-
radic cases (21 %), the available sample size of the study 
population did not provide sufficient statistical power to 
test the difference between familial and sporadic AAA 
(Table 5).
COL3A1
The vascular type of the Ehlers–Danlos syndrome has 
caused mutations in type III procollagen encoded by the 
COL3A1 gene (Pepin et al. 2000). Abnormal type III pro-
collagen results in altered connective tissue in particular of 
the vascular wall, skin and inner organs. The Ehlers–Dan-
los type IV syndrome is associated with vascular fragility, 
thin and translucent skin, typical facial features, rupture 
uterus or intestines, and variably hypermobility or contrac-
tures. In the COL3A1 gene we found one familial patho-
genic null mutation and two VUS variants in familial AAA. 
Null mutations in COL3A1 cause haploinsufficiency and 
were previously associated with attenuated clinical features 
of the vascular type of Ehlers–Danlos syndrome, like in the 
family described in the current study (Leistritz et al. 2011).
EFEMP2
No pathogenic EFEMP2 variants were detected in AAA 
patients. Four LB variants were observed in five familial 
AAA patients (8 %). One patient had two different vari-
ants in EFEMP2. One LB variant with an allele frequency 
of 0.005 in the Dutch population occurred in three patients.
FBN1
The Marfan syndrome (MFS) was the first well-recognized 
genetic aortic aneurysm syndrome described in 1896, 
(Marfan 1896) and has an estimated prevalence of 2–3 
per 10,000 individuals equally affecting men and women 
(Pyeritz and McKusick 1979). We found five FBN1 VUS, 
two in familial and three in sporadic patients including 
three VUS previously reported in aneurysm patients in 
HGMD (Table 2).
MYH11
One likely pathogenic segregating variant and five VUS 
were observed among the ten rare variants in this gene.
MYLK
The MYLK gene harbored the most variants of all exam-
ined genes in this study in familial and sporadic patients. 
We found 13 unique variants in 18 patients, in 13 % of the 
familial and 13 % of the sporadic AAA patients. Of these 
variants, five were VUS and the rest was classified as likely 
benign.
TGFB2
Boileau and Lindsay et al. described simultaneously a 
mutation in the TGFB2 gene causing familial thoracic 
aortic aneurysm and dissections and overlapping clinical 
features with Loeys–Dietz syndrome (Boileau et al. 2012; 
Lindsay et al. 2012). We observed two VUS in the TGFB2 
in two patients with familial AAA (6 %).
Table 5  Genetic variants in 
99 familial and 56 sporadic 
abdominal aortic aneurysm 
patients
LP likely pathogenic, P pathogenic, All variants: pathogenic, likely pathogenic, unknown clinical signifi-
cance and likely benign
* P value was calculated using the two-tailed Fisher’s exact test
Gene/variants Total AAA patients Familial AAA patients Sporadic AAA patients p value
n ALL LP/P n ALL LP/P n All LP/P ALL LP/P
ACTA2 139 0 0 92 0 0 47 0 0 1 1
COL3A1 122 3 (2 %) 1 (1 %) 82 3 (2 %) 1 (1 %) 40 0 0 1 1
EFEMP2 89 5 (7 %) 0 65 5 (8 %) 0 24 0 0 0.19 1
FBN1 127 8 (6 %) 0 85 5 (6 %) 0 42 3 (7 %) 0 1 1
MYH11 133 11 (8 %) 1 (1 %) 90 9 (10 %) 1 (1 %) 43 2 (5 %) 0 0.50 1
MYLK 136 18 (13 %) 0 90 12 (13 %) 0 46 6 (13 %) 0 1 1
SMAD3 142 0 0 94 0 0 48 0 0 1 1
TGFB2 65 2 (3 %) 0 40 2 (5 %) 0 25 0 0 0.52 1
TGFBR1 141 5 (4 %) 0 93 4 (4 %) 0 48 1 (2 %) 0 0.66 1
TGFBR2 140 3 (2 %) 1 (1 %) 94 2 (2 %) 0 46 1 (2 %) 1 (2 %) 1 0.33
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TGFBR1 and TGFBR2
In TGFBR1 we found variants in 4 % of familial and 2 % of 
sporadic patients, one VUS and three likely benign. To our 
knowledge no pathogenic variants in TGFBR1 or TGFBR2 
have been linked to familial AAA. Specific alleles were 
previously associated with risk for AAA (Baas et al. 2010; 
Lucarini et al. 2009).
In TGFBR2, we found one de novo pathogenic novel 
single base pair deletion leading to a truncated protein. 
We also found one missense variant that was reported in 
HGMD and was classified as VUS, and one variant that we 
classified as likely benign.
MTHFR
The role in the susceptibility for abdominal aortic aneu-
rysms of the MTHFR c.665C>T (p.Ala222Val) variant, 
previously reported as C677T, was investigated by a num-
ber of case–control studies showing more robust associa-
tions in some than in others (Narayanan et al. 2013). More 
recently, genome-wide association studies endorsed that 
this variant was associated with an increased risk (Brunelli 
et al. 2000; Ferrara et al. 2006; Jones et al. 2005; Sofi et al. 
2005; Strauss et al. 2003). In the current study, the MAF of 
the risk allele was lower (0.265) than in the Dutch control 
population (0.320), indicating that our data did not support 
a link with AAA.
Concluding remarks
This study identified three causal variants in a set of genes 
previously associated with familial thoracic aortic aneu-
rysms in 155 familial and sporadic AAA patients. Our 
results showed that diagnostic testing of these aneurysm 
genes might help find the cause for AAA and help to accu-
rately identify relatives at risk. It is important to note the 
occurrence of de novo mutations, indicating that a negative 
family history should not preclude genetic testing. Patho-
genic variants were found in two younger male patients 
with complex vascular features and an elderly female AAA 
patient. Although we cannot exclude an effect of referral 
bias, these observations merit further studies addressing the 
question whether age, gender and clinical features define a 
risk profile for molecular defects in AAA patients.
The identification of 44 other variants in genes associ-
ated with hereditary thoracic aneurysms suggests a more 
important contribution of these genes in AAA than known 
before. We expect that additional aneurysm-associated 
genes will be detected in the future because the majority 
of familial AAA patients had no variants in the examined 
genes.
Acknowledgments This study was supported by grants from the 
“Lijf en Leven” Foundation, Rotterdam, The Netherlands.
Conflict of interest Dr Verhagen reports consultancy fees for 
Medtronic Inc, USA and Gore Inc., USA. No other disclosures were 
reported.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.
References
Andreasen NC, Endicott J, Spitzer RL, Winokur G (1977) The family 
history method using diagnostic criteria. Reliability and validity. 
Arch Gen Psychiatry 34:1229–1235
Arbustini E, Grasso M, Ansaldi S, Malattia C, Pilotto A, Porcu E, Dis-
abella E, Marziliano N, Pisani A, Lanzarini L, Mannarino S, Lar-
izza D, Mosconi M, Antoniazzi E, Zoia MC, Meloni G, Magrassi 
L, Brega A, Bedeschi MF, Torrente I, Mari F, Tavazzi L (2005) 
Identification of sixty-two novel and twelve known FBN1 muta-
tions in eighty-one unrelated probands with Marfan syndrome 
and other fibrillinopathies. Hum Mutat 26:494
Baas AF, Medic J, van’t Slot R, de Kovel CG, Zhernakova A, Geel-
kerken RH, Kranendonk SE, van Sterkenburg SM, Grobbee DE, 
Boll AP, Wijmenga C, Blankensteijn JD, Ruigrok YM (2010) 
Association of the TGF-beta receptor genes with abdominal aor-
tic aneurysm. Eur J Hum Genet 18:240–244
Boileau C, Guo DC, Hanna N, Regalado ES, Detaint D, Gong L, Var-
ret M, Prakash SK, Li AH, d’Indy H, Braverman AC, Grand-
champ B, Kwartler CS, Gouya L, Santos-Cortez RL, Abifadel 
M, Leal SM, Muti C, Shendure J, Gross MS, Rieder MJ, Vaha-
nian A, Nickerson DA, Michel JB, Jondeau G, Milewicz DM 
(2012) TGFB2 mutations cause familial thoracic aortic aneu-
rysms and dissections associated with mild systemic features of 
Marfan syndrome. Nat Genet 44:916–921
Bown MJ, Jones GT, Harrison SC, Wright BJ, Bumpstead S, Baas 
AF, Gretarsdottir S, Badger SA, Bradley DT, Burnand K, Child 
AH, Clough RE, Cockerill G, Hafez H, Scott DJ, Futers S, John-
son A, Sohrabi S, Smith A, Thompson MM, van Bockxmeer 
FM, Waltham M, Matthiasson SE, Thorleifsson G, Thorstein-
sdottir U, Blankensteijn JD, Teijink JA, Wijmenga C, de Graaf 
J, Kiemeney LA, Assimes TL, McPherson R, Consortium CA, 
Global BC, Consortium D, Consortium V, Folkersen L, Franco-
Cereceda A, Palmen J, Smith AJ, Sylvius N, Wild JB, Refstrup 
M, Edkins S, Gwilliam R, Hunt SE, Potter S, Lindholt JS, 
Frikke-Schmidt R, Tybjaerg-Hansen A, Hughes AE, Golledge 
J, Norman PE, van Rij A, Powell JT, Eriksson P, Stefansson K, 
Thompson JR, Humphries SE, Sayers RD, Deloukas P, Samani 
NJ (2011) Abdominal aortic aneurysm is associated with a vari-
ant in low-density lipoprotein receptor-related protein 1. Am J 
Hum Genet 89:619–27
Brunelli T, Prisco D, Fedi S, Rogolino A, Farsi A, Marcucci R, Giusti 
B, Pratesi C, Pulli R, Gensini GF, Abbate R, Pepe G (2000) 
High prevalence of mild hyperhomocysteinemia in patients with 
abdominal aortic aneurysm. J Vasc Surg 32:531–536
Cook JR, Carta L, Galatioto J, Ramirez F (2014) Cardiovascular man-
ifestations in Marfan syndrome and related diseases; multiple 
genes causing similar phenotypes. Clin Genet
892 Hum Genet (2015) 134:881–893
1 3
Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson 
GM, Puffenberger EG, Hamosh A, Nanthakumar EJ, Curristin 
SM et al (1991) Marfan syndrome caused by a recurrent de novo 
missense mutation in the fibrillin gene. Nature 352:337–339
Ferrara F, Novo S, Grimaudo S, Raimondi F, Meli F, Amato C, Amo-
deo G, Lo Presti R, Caimi G (2006) Methylenetetrahydrofolate 
reductase mutation in subjects with abdominal aortic aneurysm 
subdivided for age. Clin Hemorheol Microcirc 34:421–426
Genome of the Netherlands C (2014) Whole-genome sequence varia-
tion, population structure and demographic history of the Dutch 
population. Nat Genet 46:818–825
Gretarsdottir S, Baas AF, Thorleifsson G, Holm H, den Heijer M, de 
Vries JP, Kranendonk SE, Zeebregts CJ, van Sterkenburg SM, 
Geelkerken RH, van Rij AM, Williams MJ, Boll AP, Kostic JP, 
Jonasdottir A, Walters GB, Masson G, Sulem P, Saemundsdottir 
J, Mouy M, Magnusson KP, Tromp G, Elmore JR, Sakalihasan 
N, Limet R, Defraigne JO, Ferrell RE, Ronkainen A, Ruigrok 
YM, Wijmenga C, Grobbee DE, Shah SH, Granger CB, Quyy-
umi AA, Vaccarino V, Patel RS, Zafari AM, Levey AI, Austin 
H, Girelli D, Pignatti PF, Olivieri O, Martinelli N, Malerba G, 
Trabetti E, Becker LC, Becker DM, Reilly MP, Rader DJ, Muel-
ler T, Dieplinger B, Haltmayer M, Urbonavicius S, Lindblad B, 
Gottsater A, Gaetani E, Pola R, Wells P, Rodger M, Forgie M, 
Langlois N, Corral J, Vicente V, Fontcuberta J, Espana F, Grarup 
N, Jorgensen T, Witte DR, Hansen T, Pedersen O, Aben KK, de 
Graaf J, Holewijn S, Folkersen L, Franco-Cereceda A, Eriks-
son P, Collier DA, Stefansson H, Steinthorsdottir V, Rafnar T, 
Valdimarsson EM, Magnadottir HB, Sveinbjornsdottir S, Olafs-
son I, Magnusson MK, Palmason R, Haraldsdottir V, Andersen 
K, Onundarson PT, Thorgeirsson G, Kiemeney LA, Powell JT, 
Carey DJ, Kuivaniemi H, Lindholt JS, Jones GT, Kong A, Blank-
ensteijn JD, Matthiasson SE, Thorsteinsdottir U et al (2010) 
Genome-wide association study identifies a sequence variant 
within the DAB2IP gene conferring susceptibility to abdominal 
aortic aneurysm. Nat Genet 42:692–697
Guo DC, Pannu H, Tran-Fadulu V, Papke CL, Yu RK, Avidan N, 
Bourgeois S, Estrera AL, Safi HJ, Sparks E, Amor D, Ades L, 
McConnell V, Willoughby CE, Abuelo D, Willing M, Lewis 
RA, Kim DH, Scherer S, Tung PP, Ahn C, Buja LM, Raman CS, 
Shete SS, Milewicz DM (2007) Mutations in smooth muscle 
alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dis-
sections. Nat Genet 39:1488–1493
Helgadottir A, Thorleifsson G, Magnusson KP, Gretarsdottir S, 
Steinthorsdottir V, Manolescu A, Jones GT, Rinkel GJ, Blank-
ensteijn JD, Ronkainen A, Jaaskelainen JE, Kyo Y, Lenk GM, 
Sakalihasan N, Kostulas K, Gottsater A, Flex A, Stefansson 
H, Hansen T, Andersen G, Weinsheimer S, Borch-Johnsen K, 
Jorgensen T, Shah SH, Quyyumi AA, Granger CB, Reilly MP, 
Austin H, Levey AI, Vaccarino V, Palsdottir E, Walters GB, Jon-
sdottir T, Snorradottir S, Magnusdottir D, Gudmundsson G, Fer-
rell RE, Sveinbjornsdottir S, Hernesniemi J, Niemela M, Limet 
R, Andersen K, Sigurdsson G, Benediktsson R, Verhoeven EL, 
Teijink JA, Grobbee DE, Rader DJ, Collier DA, Pedersen O, 
Pola R, Hillert J, Lindblad B, Valdimarsson EM, Magnadottir 
HB, Wijmenga C, Tromp G, Baas AF, Ruigrok YM, van Rij AM, 
Kuivaniemi H, Powell JT, Matthiasson SE, Gulcher JR, Thor-
geirsson G, Kong A, Thorsteinsdottir U, Stefansson K (2008) 
The same sequence variant on 9p21 associates with myocardial 
infarction, abdominal aortic aneurysm and intracranial aneu-
rysm. Nat Genet 40:217–224
Hucthagowder V, Sausgruber N, Kim KH, Angle B, Marmorstein LY, 
Urban Z (2006) Fibulin-4: a novel gene for an autosomal reces-
sive cutis laxa syndrome. Am J Hum Genet 78:1075–1080
Hung CC, Lin SY, Lee CN, Cheng HY, Lin SP, Chen MR, Chen CP, 
Chang CH, Lin CY, Yu CC, Chiu HH, Cheng WF, Ho HN, Niu 
DM, Su YN (2009) Mutation spectrum of the fibrillin-1 (FBN1) 
gene in Taiwanese patients with Marfan syndrome. Ann Hum 
Genet 73:559–567
Jones GT, Harris EL, Phillips LV, van Rij AM (2005) The methyl-
enetetrahydrofolate reductase C677T polymorphism does not 
associate with susceptibility to abdominal aortic aneurysm. Eur J 
Vasc Endovasc Surg 30:137–142
Jones GT, Bown MJ, Gretarsdottir S, Romaine SP, Helgadottir A, 
Yu G, Tromp G, Norman PE, Jin C, Baas AF, Blankensteijn 
JD, Kullo IJ, Phillips LV, Williams MJ, Topless R, Merriman 
TR, Vasudevan TM, Lewis DR, Blair RD, Hill AA, Sayers RD, 
Powell JT, Deloukas P, Thorleifsson G, Matthiasson SE, Thor-
steinsdottir U, Golledge J, Ariens RA, Johnson A, Sohrabi S, 
Scott DJ, Carey DJ, Erdman R, Elmore JR, Kuivaniemi H, Sam-
ani NJ, Stefansson K, van Rij AM (2013) A sequence variant 
associated with sortilin-1 (SORT1) on 1p13.3 is independently 
associated with abdominal aortic aneurysm. Hum Mol Genet 
22:2941–2947
Judge DP, Dietz HC (2005) Marfan’s syndrome. Lancet 
366:1965–1976
Kappanayil M, Nampoothiri S, Kannan R, Renard M, Coucke P, 
Malfait F, Menon S, Ravindran HK, Kurup R, Faiyaz-Ul-Haque 
M, Kumar K, De Paepe A (2012) Characterization of a distinct 
lethal arteriopathy syndrome in twenty-two infants associated 
with an identical, novel mutation in FBLN4 gene, confirms fibu-
lin-4 as a critical determinant of human vascular elastogenesis. 
Orphanet J Rare Dis 7:61
Kuang SQ, Kwartler CS, Byanova KL, Pham J, Gong L, Prakash 
SK, Huang J, Kamm KE, Stull JT, Sweeney HL, Milewicz DM 
(2012) Rare, nonsynonymous variant in the smooth muscle-
specific isoform of myosin heavy chain, MYH11, R247C, alters 
force generation in the aorta and phenotype of smooth muscle 
cells. Circ Res 110:1411–1422
Leistritz DF, Pepin MG, Schwarze U, Byers PH (2011) COL3A1 hap-
loinsufficiency results in a variety of Ehlers-Danlos syndrome 
type IV with delayed onset of complications and longer life 
expectancy. Genet Med 13:717–722
Lindsay ME, Schepers D, Bolar NA, Doyle JJ, Gallo E, Fert-Bober J, 
Kempers MJ, Fishman EK, Chen Y, Myers L, Bjeda D, Oswald 
G, Elias AF, Levy HP, Anderlid BM, Yang MH, Bongers EM, 
Timmermans J, Braverman AC, Canham N, Mortier GR, Brun-
ner HG, Byers PH, Van Eyk J, Van Laer L, Dietz HC, Loeys BL 
(2012) Loss-of-function mutations in TGFB2 cause a syndromic 
presentation of thoracic aortic aneurysm. Nat Genet 44:922–927
Loeys BL, Chen J, Neptune ER, Judge DP, Podowski M, Holm T, 
Meyers J, Leitch CC, Katsanis N, Sharifi N, Xu FL, Myers LA, 
Spevak PJ, Cameron DE, De Backer J, Hellemans J, Chen Y, 
Davis EC, Webb CL, Kress W, Coucke P, Rifkin DB, De Paepe 
AM, Dietz HC (2005) A syndrome of altered cardiovascular, 
craniofacial, neurocognitive and skeletal development caused by 
mutations in TGFBR1 or TGFBR2. Nat Genet 37:275–281
Loeys BL, Schwarze U, Holm T, Callewaert BL, Thomas GH, Pannu 
H, De Backer JF, Oswald GL, Symoens S, Manouvrier S, Rob-
erts AE, Faravelli F, Greco MA, Pyeritz RE, Milewicz DM, 
Coucke PJ, Cameron DE, Braverman AC, Byers PH, De Paepe 
AM, Dietz HC (2006) Aneurysm syndromes caused by muta-
tions in the TGF-beta receptor. N Engl J Med 355:788–798
Lucarini L, Sticchi E, Sofi F, Pratesi G, Pratesi C, Pulli R, Gensini 
GF, Abbate R, Pepe G, Fatini C (2009) ACE and TGFBR1 genes 
interact in influencing the susceptibility to abdominal aortic 
aneurysm. Atherosclerosis 202:205–210
MacArthur DG, Manolio TA, Dimmock DP, Rehm HL, Shendure J, 
Abecasis GR, Adams DR, Altman RB, Antonarakis SE, Ashley 
EA, Barrett JC, Biesecker LG, Conrad DF, Cooper GM, Cox 
NJ, Daly MJ, Gerstein MB, Goldstein DB, Hirschhorn JN, Leal 
SM, Pennacchio LA, Stamatoyannopoulos JA, Sunyaev SR, 
Valle D, Voight BF, Winckler W, Gunter C (2014) Guidelines for 
893Hum Genet (2015) 134:881–893 
1 3
investigating causality of sequence variants in human disease. 
Nature 508:469–476
Marfan A (1896) Un cas de deformation congenitale des qua-
tre membres plus prononcee aux extremites caracterisee par 
l’allongement des os avec un certain degre d’amincissement. 
Bull Mem Soc Med Hop Paris 13:220–226
Matyas G, Arnold E, Carrel T, Baumgartner D, Boileau C, Berger W, 
Steinmann B (2006) Identification and in silico analyses of novel 
TGFBR1 and TGFBR2 mutations in Marfan syndrome-related 
disorders. Hum Mutat 27:760–769
Moll FL, Powell JT, Fraedrich G, Verzini F, Haulon S, Waltham 
M, van Herwaarden JA, Holt PJ, van Keulen JW, Rantner B, 
Schlosser FJ, Setacci F, Ricco JB (2011) Management of abdom-
inal aortic aneurysms clinical practice guidelines of the Euro-
pean society for vascular surgery. Eur J Vasc Endovasc Surg 
41(Suppl 1):S1–S58
Morisaki H, Akutsu K, Ogino H, Kondo N, Yamanaka I, Tsutsumi 
Y, Yoshimuta T, Okajima T, Matsuda H, Minatoya K, Sasaki H, 
Tanaka H, Ishibashi-Ueda H, Morisaki T (2009) Mutation of 
ACTA2 gene as an important cause of familial and nonfamil-
ial nonsyndromatic thoracic aortic aneurysm and/or dissection 
(TAAD). Hum Mutat 30:1406–1411
Narayanan N, Tyagi N, Shah A, Pagni S, Tyagi SC (2013) Hyperho-
mocysteinemia during aortic aneurysm, a plausible role of epige-
netics. Int J Physiol Pathophysiol Pharmacol 5:32–42
Pannu H, Tran-Fadulu V, Papke CL, Scherer S, Liu Y, Presley C, Guo 
D, Estrera AL, Safi HJ, Brasier AR, Vick GW, Marian AJ, Raman 
CS, Buja LM, Milewicz DM (2007) MYH11 mutations result in 
a distinct vascular pathology driven by insulin-like growth factor 
1 and angiotensin II. Hum Mol Genet 16:2453–2462
Pepin M, Schwarze U, Superti-Furga A, Byers PH (2000) Clinical and 
genetic features of Ehlers-Danlos syndrome type IV, the vascular 
type. N Engl J Med 342:673–680
Pickup MJ, Pollanen MS (2011) Traumatic subarachnoid hemorrhage 
and the COL3A1 gene: emergence of a potential causal link. 
Forensic Sci Med Pathol 7:192–197
Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenb-
latt MS, Hogervorst FB, Hoogerbrugge N, Spurdle AB, Tavtig-
ian SV, Group IUGVW (2008) Sequence variant classification 
and reporting: recommendations for improving the interpreta-
tion of cancer susceptibility genetic test results. Hum Mutat 
29:1282–1291
Pomianowski P, Elefteriades JA (2013) The genetics and genomics of 
thoracic aortic disease. Ann Cardiothorac Surg 2:271–279
Pyeritz RE, McKusick VA (1979) The Marfan syndrome: diagnosis 
and management. N Engl J Med 300:772–777
Renard M, Callewaert B, Baetens M, Campens L, MacDermot K, 
Fryns JP, Bonduelle M, Dietz HC, Gaspar IM, Cavaco D, Stattin 
EL, Schrander-Stumpel C, Coucke P, Loeys B, De Paepe A, De 
Backer J (2013) Novel MYH11 and ACTA2 mutations reveal a 
role for enhanced TGFbeta signaling in FTAAD. Int J Cardiol 
165:314–321
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody 
WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm 
HL (2015) Standards and guidelines for the interpretation of 
sequence variants: a joint consensus recommendation of the 
American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology. Genet Med
Rossaak JI, Hill TM, Jones GT, Phillips LV, Harris EL, van Rij AM 
(2001) Familial abdominal aortic aneurysms in the Otago region 
of New Zealand. Cardiovasc Surg 9:241–248
Salo JA, Soisalon-Soininen S, Bondestam S, Mattila PS (1999) Famil-
ial occurrence of abdominal aortic aneurysm. Ann Intern Med 
130:637–642
Sheikhzadeh S, Kade C, Keyser B, Stuhrmann M, Arslan-Kirchner 
M, Rybczynski M, Bernhardt AM, Habermann CR, Hillebrand 
M, Mir T, Robinson PN, Berger J, Detter C, Blankenberg S, 
Schmidtke J, von Kodolitsch Y (2012) Analysis of phenotype 
and genotype information for the diagnosis of Marfan syndrome. 
Clin Genet 82:240–247
Sofi F, Marcucci R, Giusti B, Pratesi G, Lari B, Sestini I, Lo Sapio P, 
Pulli R, Pratesi C, Abbate R, Gensini GF (2005) High levels of 
homocysteine, lipoprotein (a) and plasminogen activator inhibi-
tor-1 are present in patients with abdominal aortic aneurysm. 
Thromb Haemost 94:1094–1098
Strauss E, Waliszewski K, Gabriel M, Zapalski S, Pawlak AL (2003) 
Increased risk of the abdominal aortic aneurysm in carriers of the 
MTHFR 677T allele. J Appl Genet 44:85–93
ten Dijke P, Arthur HM (2007) Extracellular control of TGFbeta sig-
nalling in vascular development and disease. Nat Rev Mol Cell 
Biol 8:857–869
Thompson AR, Drenos F, Hafez H, Humphries SE (2008) Candi-
date gene association studies in abdominal aortic aneurysm 
disease: a review and meta-analysis. Eur J Vasc Endovasc Surg 
35:19–30
van de Laar IM, Oldenburg RA, Pals G, Roos-Hesselink JW, de Graaf 
BM, Verhagen JM, Hoedemaekers YM, Willemsen R, Severijnen 
LA, Venselaar H, Vriend G, Pattynama PM, Collee M, Majoor-
Krakauer D, Poldermans D, Frohn-Mulder IM, Micha D, Tim-
mermans J, Hilhorst-Hofstee Y, Bierma-Zeinstra SM, Willems 
PJ, Kros JM, Oei EH, Oostra BA, Wessels MW, Bertoli-Avella 
AM (2011) Mutations in SMAD3 cause a syndromic form of 
aortic aneurysms and dissections with early-onset osteoarthritis. 
Nat Genet 43:121–126
van de Luijtgaarden KM, Bastos Goncalves F, Majoor-Krakauer D, 
Verhagen HJ (2013) Arterial elongation and tortuosity leads to 
detection of a de novo TGFBR2 mutation in a young patient with 
complex aortic pathology. Eur Heart J 34:1133
van de Luijtgaarden KM, Bastos Goncalves F, Hoeks SE, Valentijn 
TM, Stolker RJ, Majoor-Krakauer D, Verhagen HJ, Rouwet EV 
(2014) Lower atherosclerotic burden in familial abdominal aortic 
aneurysm. J Vasc Surg 59:589–593
Wang L, Guo DC, Cao J, Gong L, Kamm KE, Regalado E, Li L, 
Shete S, He WQ, Zhu MS, Offermanns S, Gilchrist D, Elefteri-
ades J, Stull JT, Milewicz DM (2010) Mutations in myosin light 
chain kinase cause familial aortic dissections. Am J Hum Genet 
87:701–707
